Test a dye used during surgery to find head and neck cancer
Part of Cancer clinical trials.
This trial tests whether a single dose of an imaging dye (given during surgery) can help doctors find the unknown origin of head and neck cancer and check safety. It may help guide surgery and biopsies when the primary cancer location hasn’t been identified.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18 or older).
- You have confirmed head and neck cancer on biopsy, or a strong suspicion of it (as judged by the study doctor).
- You can have surgery for this cancer (the surgeon must feel imaging during the operation is possible).
- Your overall health is good enough for surgery (for example, not too ill, with adequate ability to follow the study visits).
- If you can get pregnant: you must have a negative pregnancy test and use reliable birth control during the study and for 6 months after.
- You agree not to drink alcohol starting 72 hours before the dye is given until the Day 10 visit (plus or minus about 2 days).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage study tests two different imaging (scanning) methods to better detect head and neck cancer. Your results from the scans may help doctors see where disease is before standard surgery to remove lymph nodes in the neck.
This trial uses a special PET scan to look at head and neck cancer cells before treatment. It may help doctors learn more about your cancer and decide if different treatments could work better for you.
This Phase 1 study tests a labelling of panitumumab with iodine (111In) to see how well it can identify lymph nodes in head and neck cancer before surgery. The goal is to improve lymph node staging (which can help guide treatment), with the main focus on safety and early performance.
This trial tests a combination of three drugs (becotatug vedotin, pucotenlimab, and cisplatin) given before surgery for head and neck cancer that has not spread far. The goal is to see if this treatment shrinks tumors and improves outcomes for patients with stage 3 or 4A disease.
This early-phase study compares a special imaging marker with a standard PET scan to help identify head and neck squamous cell carcinoma before surgery. It may help doctors see where cancer is (especially if lymph nodes look negative) so surgery planning can be more accurate.
This study tests whether two special imaging agents can help doctors see head and neck cancer more clearly during surgery. It may help surgeons remove the cancer more completely while sparing healthy tissue.
Hear when a new Head and Neck Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.